Adiponectin Testing Market Outlook:
Adiponectin Testing Market size was over USD 55.24 billion in 2025 and is projected to reach USD 117.07 billion by 2035, witnessing around 7.8% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of adiponectin testing is evaluated at USD 59.12 billion.
The growth of the market can be attributed to the rising adoption of adipose-derived products and the growing prevalence of cardiometabolic diseases across the globe. For instance, it is observed that about 1 out of 1,000 people have some sort of metabolic disease worldwide. Additionally, the increasing awareness of people on health and early diagnostic testing is estimated to drive market growth. Further, the rising living standards of people spend on healthcare needs and necessary testing is anticipated to have a positive impact on market growth in coming years.
Adiponectin is a type of protein hormone that is responsible for the modulation of multiple metabolic processes. Common types of metabolic diseases are diabetes, cystinuria, phenylketonuria (PKU), albinism, and others. A report by The National Library of Medicine (NLM) showed that 1 in 7,000 people have cystinuria globally. Furthermore, the growing number of obese populations is also projected to hike the growth of the market over the forecast period. For instance, various academic types of research demonstrated that more than 39% of adults are overweight while around 13% of adults are obese across the globe. All these factors are projected to influence the growth of the market positively over the forecast period.
